← Leaderboards
Stuart J Kahn
University Of Washington
$11,904,993
Attributed
$20,502,469
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2008–21$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$20,502,469 · 11
By mechanism
R44$14,808,099 · 6
R01$2,788,890 · 2
U44$1,668,787 · 1
R43$1,236,693 · 2
Top collaborators
- John A Zebala23 shared
- Dean Yoshimasa Maeda3 shared
Most similar at University Of Washington
Same institution · by research overlap
- Jashvant D Unadkat$14,909,800
- Joanne Wang$8,239,883
- Joshua Woodward$10,445,693
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsSafetyDoseOralCostCyclic GmpAdverse EffectsBaseClinicSmall Business Innovation Research GrantUnited StatesResistanceResearch Clinical TestingRandomizedInflammationPhase I Clinical TrialsReportingInterestPlacebosSuccessDisease RemissionAffectEnantiomerDouble-Blind Method
Grant awards (37)
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$651,354
R44 · FY2021 · CA · contact PI
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$80,191
R44 · FY2021 · DA · contact PI
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,575,472
R44 · FY2020 · HL · contact PI
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$1,204,753
R44 · FY2020 · DA · contact PI
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$223,334
R44 · FY2020 · CA · contact PI
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$1,424,426
R44 · FY2019 · HL · contact PI
A Phase 1 Randomized Single Oral Dose Four Period Cross-Over Study Investigating Omnitram Dose Proportionality and Food Effect in Normal Human Subjects$204,489
R44 · FY2019 · DA · contact PI
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$1,125,311
R44 · FY2018 · CA · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$977,024
R44 · FY2018 · DA · contact PI
HLS- A Phase 1 Open-Label Dose-Escalation with Expansion Study of SX-682 in MDS Patients$398,444
R44 · FY2018 · HL · contact PI
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$304,057
U44 · FY2018 · AI · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$997,596
R44 · FY2017 · DA · contact PI
Phase II clinical evaluation of Omnitram in neuropathic pain$657,180
R44 · FY2017 · DA · contact PI
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$649,697
U44 · FY2017 · AI · contact PI
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma$621,000
R44 · FY2017 · CA · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers: A Phase 1 Trial Demonstrating Analgesic Superiority of Omnitram to Tramadol in Subjects Coadministered Paroxetine$990,418
R44 · FY2016 · DA · contact PI
Phase II clinical evaluation of Omnitram in neuropathic pain$842,819
R44 · FY2016 · DA · contact PI
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$490,033
U44 · FY2016 · AI · contact PI
Phase II clinical evaluation of Omnitram in neuropathic pain$224,997
R44 · FY2015 · DA · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$583,069
R44 · FY2014 · DA · contact PI
Efficacy and resistance mechanisms of LD-aminopterin in psoriasis$225,000
U44 · FY2014 · AI · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$933,466
R44 · FY2013 · DA · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$574,129
R44 · FY2012 · DA · contact PI
Overcoming Tramadol Resistance In CYP2D6 Poor Metabolizers$649,545
R43 · FY2010 · DA · contact PI
The Treatment of Methotrexate Resistant Rheumatoid Arthritis With Aminopterin$518,627
R44 · FY2009 · AR · contact PI
Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis$293,574
R43 · FY2009 · AR · contact PI
Aminopterin for the Treatment of Severe Recalcitrant Atopic Dermatitis$293,574
R43 · FY2008 · AR · contact PI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2004 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2004 · AI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2003 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2003 · AI
The Function of NKT Cells During T Cruzi Infection$384,750
R01 · FY2002 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$342,000
R01 · FY2002 · AI
The Function of NKT Cells During T Cruzi Infection$304,835
R01 · FY2001 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$248,300
R01 · FY2001 · AI
The Function of NKT Cells During T Cruzi Infection$30,925
R01 · FY2001 · AI
T. cruzi-induced Protective and Pathologic CD4 Responses$24,580
R01 · FY2001 · AI